Abhishek Tripathi, MD
Dt Abhishek Tripathi is a medical oncologist specializing in genitourinary malignancies in the Department of Medical Oncology and Therapeutics Research at the City of Hope comprehensive Cancer Center. Prior to joining City of Hope in 2022, he served on the faculty of the University of Oklahoma Stephenson Cancer Center. As a clinical investigator, his interests are developmental therapeutics, novel biomarkers and development of innovative clinical trials. He has authored numerous peer-reviewed research publications and his research has been presented at numerous national and international meetings. At the American Society of Clinical Oncology’s 2017 symposium on genitourinary cancers, Dr. Tripathi was recognized with the Conquer Cancer Foundation of ASCO Merit Award. He was also selected to participate in a competitive workshop on clinical cancer research presented by ASCO and the American Association for Clinical Research. During his fellowship in oncology/hematology at the University of Massachusetts, he served a stint as chief fellow. He is an active member of the NCI sponsored SWOG and ECOG genitourinary cancer committee.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Deka BiosciencesTopic:Renal cell carcinomaDate added:07/20/2023Date updated:07/20/2023Relationship end date:07/31/2022
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:EMD SeronoTopic:bladder cancerDate added:07/20/2023Date updated:07/20/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Aravive IncTopic:bladder cancerDate added:07/20/2023Date updated:07/20/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:ExelixisTopic:renal cell carcinomaDate added:07/20/2023Date updated:07/20/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Seattle GeneticsTopic:Bladder CancerDate added:07/20/2023Date updated:07/20/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BayerTopic:Prostate CancerDate added:07/20/2023Date updated:07/20/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:SanofiTopic:Prostate cancerDate added:07/20/2023Date updated:07/20/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Aldi BiosciencesTopic:Renal cell carcinomaDate added:07/20/2023Date updated:07/20/2023